Progress in the development of PET radiotracers has enabled the noninvasive assessment of the pathological hallmarks of Alzheimer disease (AD) and other neurodegenerative disorders. New reports have revealed the potential usefulness of tau PET imaging in AD and non-AD tauopathies.
Refers to Pontecorvo, M. J. et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140, 748-763 (2017) | Passamonti, L. et al.18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain 140, 781-791 (2017)